Workflow
α粒子放射性体内治疗
icon
Search documents
烟台东诚药业集团股份有限公司 关于控股子公司获得药物临床试验批准通知书的公告
Core Viewpoint - Yantai Dongcheng Pharmaceutical Group Co., Ltd. announced that its subsidiary, Yantai Lanacheng Biotechnology Co., Ltd., received approval from the National Medical Products Administration for clinical trials of the drug 225Ac-LNC1011, which targets advanced prostate cancer patients expressing Prostate Specific Membrane Antigen (PSMA) [1][2]. Drug Information - 225Ac-LNC1011 is an alpha-particle radioactive internal therapy drug targeting PSMA, designed for treating patients with advanced prostate cancer. Compared to traditional beta-particles, alpha-particles have a short range (<100 μm), high energy deposition (80-100 keV/μm), and multi-stage alpha decay, providing stronger cell-killing effects while minimizing damage to surrounding healthy tissues [1][2]. Clinical Trial and Development - The drug has shown excellent pharmacokinetic properties and significant efficacy in completed animal and human trials, indicating its potential as a more effective PSMA-targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). Currently, there are no similar products available in the domestic or international markets, and no related sales data exists [2]. - The total research and development expenses for the 225Ac-LNC1011 project have reached approximately 14.53 million yuan [2].